Previous close | 37.00 |
Open | N/A |
Bid | 38.70 |
Ask | 42.90 |
Strike | 45.00 |
Expiry date | 2025-01-17 |
Day's range | 37.00 - 37.00 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Edwards Lifesciences stock underperformed its peers on Friday, sliding on light sales of its transcatheter aortic heart-valve replacements.
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.